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proceeds on MCs as the result of increased expression of endog-Coagulation process proceeds on cultured human mesangial
enous factor V activity on its cell surface in cooperation withcells via expression of factor V.
exogenous factor Xa.Background. In a previous clinicopathological study, we ob-
served mesangial factor V expression accompanied by the in-
tact form of cross-linked fibrin deposition in the active type of
IgA nephropathy. The conversion of prothrombin to thrombin
by factor Xa is potently accelerated more than 104-fold by the It is thought that intraglomerular coagulation is in-
presence of factor V, which is a membrane-bound cofactor. volved in the development of glomerular injury. We have
Another membrane-bound cofactor, tissue factor, is known to
reported that the intact form of cross-linked fibrin (XFb)play an initiating role in the coagulation cascade and to be
was detected often in the mesangial areas in active typessynthesized in mesangial cells (MCs) by the stimulation of tumor
necrosis factor- (TNF-). However, the synthesis of factor V, of mesangioproliferative glomerulonephritis with the
which plays on the terminating stage of prothrombin activation, combined use of monoclonal antibody DD3B6/22 against
has not been reported previously in MCs by in vitro study.
d-dimer and plasmin exposure to the biopsy specimensOur current study tested the coagulation process via expression
[1]. The mesangial presence of intact XFb shows that itof factor V by the stimulation of proinflammatory cytokine,
TNF-, in cultured human MCs. is produced in the mesangial area. It is known that tumor
Methods. To evaluate factor V protein expression, immuno- necrosis factor- (TNF-) induces procoagulant activity
peroxidase staining with densitometric evaluation and Western in endothelial cells [2], and is one of the factors clarifiedblot analysis were conducted after stimulation of TNF-. To
to be the tissue factor that leads to fibrin deposition intest factor V activity, stimulated MCs were incubated in combi-
the circulatory system [3]. It is also established that mesan-nation with factor Xa, prothrombin, fibrinogen and factor XIII,
and fibrin production on MCs was assessed after immunoperox- gial cells (MCs) produce tissue factor-like procoagulant
idase staining on the cell surface. In a blocking test using an activity by the stimulation of TNF- [4]. Factor V in its
antibody against factor V, suppression of fibrin production
active form (Va) serves as a membrane-bound cofactorwas evaluated to clarify the role of factor V activity. For the
to factor Xa, which promotes activation of prothrombinevaluation of factor V mRNA expression in cultured human
MCs, in situ hybridization and Northern blot analysis were to thrombin. Although the conversion by factor Xa is a
performed. rather slow process, this conversion is potently acceler-
Results. Factor V protein expression in MCs after TNF- ated more than 104-fold by the coexistence of factor Vastimulation increased both time- and dose-dependently. As a
[5]. In this context, we recently observed mesangial fac-marker of factor V activity with exogenous factor Xa, fibrin
production on TNF-–stimulated MCs was increased in a time- tor V expression colocalized with fibrin deposition in the
dependent manner and was inhibited by the addition of anti- active type of IgA nephropathy [6].
factor V antibody. Factor V mRNA was identified in MCs by Based on these results, we postulated that stimulation
in situ hybridization and showed an increase after stimulation
of proinflammatory cytokine TNF- to MCs contributedwith TNF- on Northern blot analysis.
to the expression of factor V. However, the synthesis ofConclusions. Our data suggest that the coagulation process
factor V in cultured MCs has not previously been re-
ported. Therefore, our current work examined the coagu-
Key words: cross-linked fibrin, factor X, tumor necrosis factor-, IgA lation process via expression of factor V in cultured hu-nephropathy, intraglomerular coagulation, mesangioproliferative glo-
merulonephritis. man MCs when they are stimulated by TNF-. These
data may clarify the mechanisms of in vivo mesangial
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METHODS an ImmunoPure Metal Enhanced DAB Substrate kit
(Pierce, Rockford, IL, USA). MCs were counterstainedMaterials
with hematoxylin. The pixels of the staining density wasHuman fibrinogen was purified from plasma using ni-
analyzed by NIH Image version 1.61 and compared withtroblue tetrazolium (Nacalai Tesque, Kyoto, Japan) ac-
that of the control levels [10].cording to the method by Vila et al [7]. The purity was
Formation of XFb on the surface of MCs. After mono-certificated by the dot-immunobinding assay and sodium
layers of 96-hour-starved MCs (16,000 cells per chamber)dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
were stimulated by 100 U/mL of TNF- for 24 hours,PAGE) yielding two bands of 340,000 and 320,000, which
activation studies were performed at 37C by adding puri-correspond to two types of fibrinogen heterogeneity [8].
fied coagulation factors in the medium. MCs were incu-Human prothrombin was obtained from American Diag-
bated for another 0, 15, 60, or 120 minutes with 1 mLnostica (Greenwich, CT, USA). Human factor Xa was
of basal medium and each 2L of factor Xa (1.7mol/L),from Cosmo Bio (Tokyo, Japan). Factor XIII was from
prothrombin (27.7 mol/L), factor XIII (3.2 mol/L),Protogen AG (La¨ufelfingen, Switzerland), and normal
and 20 L of fibrinogen (7.6 mol/L). XFb was detectedrabbit IgG was from Zymed Laboratories (South San
indirectly after plasmin exposure using the monoclonalFrancisco, CA, USA). Recombinant human TNF- was
antibody against d-dimer, DD3B6/22 (AGEN, Brisbane,purchased from Genzyme (Kent, UK). Trypsin and Ver-
Australia), as described previously [11]. Briefly, the ac-senewere supplied by GIBCO BRL (Gaithersburg, MD,
tive form of plasmin (Nacalai Tesque, Kyoto, Japan) wasUSA). ProNectin was purchased from Protein Polymer
prepared at a concentration of 0.25 U/mL in 0.01 mol/LTechnologies (San Diego, CA, USA). The human MCs
PBS (PH 7.4). MCs on the chamber slides were incubated(Cryo NHMC, passage 5) were introduced from Bio-
with normal horse serum (Vector Laboratories) for 10Whittaker (Walkersville, MD, USA). The strain was es-
minutes to block the nonspecific antibody-binding sites.tablished and tested as fibronectin, positive; von Wille-
MCs were incubated with primary antibody DD3B6/22brand factor, negative; and cytokeratins 18 and 19,
for one hour followed by biotinylated anti-mouse IgGnegative. MCs were maintained in CC-3147 MsBM me-
(Vector Laboratories). MCs were then reacted with avi-dium (BioWhittaker) supplemented with 5% fetal calf
din-DH-biotinylated horseradish peroxidase complexserum (FCS; BioWhittaker), containing 100 U/mL peni-
(Vector Laboratories), and color was developed as de-cillin-G, and 100 g/mL streptomycin (GIBCO BRL).
scribed previously in this article. MCs were counter-MCs between passages 7 and 12 were used. All experi-
stained with hematoxylin. The staining density of XFbments were conducted using growth-arrested cells that
was analyzed as described previously in this article.were stimulated with TNF- in serum-free medium.
Blocking test for factor V activity using anti-factor V
Immunocytochemical assay antibody. Mesangial cells were starved for 96 hours and
stimulated with 100 U/mL of TNF- for 24 hours. Next,Factor V antigen expression after TNF- stimulation.
MCs were preincubated with rabbit anti-human factorCultured MCs were transferred at 16,000 cells per cham-
V antibody, RAHu/FV, of a concentration of 0, 25, orber onto Lab-Tec chamber slides (Nalge Nunc Interna-
50 g/mL of IgG to block cell surface-binding factor Vtional, Naperville, IL, USA) coated with ProNectin and
for 60 minutes. Then, the previously mentioned mixturewere starved in FCS-free basal medium for 96 hours to
of coagulation proteins was added and further incubatedwash out the cell surface-binding coagulation factors.
for 30 minutes. Normal rabbit IgG addition (50 g/mL)MCs were incubated for another 0, 3, 12, or 24 hours
was used as a control. XFb on MCs was stained andwith 100 U/mL of TNF-. In another experiment to test
analyzed as described previously in this article.dose dependency, MCs were incubated for 24 hours with
TNF- at a concentration of 0, 50, or 100 U/mL. MCs
Immunoprecipitation and immunoblottingwere then fixed in 2% paraformaldehyde in PBS for 15
Western blot after immunoprecipitation was performedminutes at 37C, washed with ice-cold PBS three times,
by the method described previously [12]. Cells (8  105)and freeze stored. Factor V in MCs on slides was detected
were starved for 96 hours, restimulated for another 0, 3,by indirect methods using a monospecific rabbit antibody
12, or 24 hours with 100 U/mL of TNF-, and lysed foragainst human factor V, RAHu/FV (Nordic Immunolog-
30 minutes in 1 mL of ice-cold lysis buffer containingical Laboratories, Tilbung, Netherlands) by the method
1% Triton X-100. After centrifugation, cell lysate wasdescribed previously [9]. Briefly, MCs on the chamber
incubated with anti-factor V antibody RAHu/FV. Theslides were incubated with the antibody RAHu/FV fol-
immune complex was incubated with protein G-Sepha-lowed by biotinylated anti-rabbit IgG (Vector Labora-
rose beads (Amersham Pharmacia, Little Chalfont, UK),tories, Burlingame, CA, USA). MCs were then reacted
and the immunoprecipitate was washed and eluted inwith avidin-DH-biotinylated horseradish peroxidase com-
1  SDS loading buffer by boiling. The protein wasplex (Vectastain ABC kit; Vector Laboratories) for 15
minutes. Color was then developed by incubation with subjected to 6% SDS-PAGE and transferred to a poly-
Ono et al: Coagulation process on MCs 1011
Fig. 1. Factor V expression after tumor ne-
crosis factor- (TNF-) stimulation in cultured
mesangial cells (MCs). MCs were fixed and
simultaneously stained for factor V. The reac-
tion color for factor V showed increasing in-
tensity after 3 (B), 12 (C), and 24 hours (D)
of incubation with TNF-, compared with con-
trol (A). This experiment was repeated three
times and essentially the same results ob-
tained. Representative data are shown (final
magnification, 190).
vinylidene difluoride (PVDF) membrane (Hybond-P; at RT for 15 minutes. Immunological detection of the
Amersham Pharmacia). The blot was incubated with hybridized probes was performed with monoclonal anti-
anti-factor V antibody and visualized with horseradish DIG, rabbit anti-mouse immunoglobulins (Dako, Car-
peroxidase-conjugated rabbit anti-rabbit IgG (Bio- pinteria, CA, USA) and mouse APAAP complex (Dako).
source, Camarillo, CA, USA) by the enhanced chemilu- Color was then developed by incubation with fast red
minescence (ECL) detection system (Amersham Phar- dye (Dako) for one hour. Finally, sections were counter-
macia). stained with hematoxylin solution. As a control, 50-fold
cold excess addition of unlabeled probes was compared.In situ hybridization for factor V mRNA
Factor V probe. To demonstrate the synthesis of factor Northern blot analysis for factor V mRNA
V by MCs, in situ hybridization for factor V was performed
Confluent MCs were cultured in serum-free basal me-using 30-mer digoxigenin (DIG)-labeled oligonucleotides,
dium for 48 hours and then with 100 U/mL of TNF-which correspond to the antisense (5-TGC ATC CCA
for 0, 3, 6, or 24 hours. RNA from these cells was purifiedGCT TGC AAA TGT TTT GGG GTG-3) of human
factor V cDNA [13]. The oligonucleotide probes were using the acid guanidium thiocyanate-phenol-chloro-
labeled with the DIG Oligonucleotide Tailing kit, using form extraction method described by Chomczynski and
a standard protocol (Boehringer Mannheim Biochemica, Sacchi [15]. Total RNA (10 g) was electrophoresed
Mannheim, Germany). in 0.66 mol/L formaldehyde–1% agarose gel and then
Procedure. Mesangial cells were starved for 48 hours transferred to a nylon membrane (Biodyne; PALL, Glen
and stimulated with 100 U/mL of TNF- for three hours. Cove, NY, USA). After prehybridization for two hours,
In situ hybridization was performed according to a modi- hybridizations were carried out at 65C overnight in hy-
fied method previously reported [14]. Briefly, the cham- bridization solution [4  SSC, 5  Denhardt’s solution,
ber slides were fixed in ice-cold 4% paraformaldehyde
50 mmol/L Tris, 10 mmol/L ethylenediaminetetraaceticfor 15 minutes. Sections were prehybridized for 1.5 hours
acid (EDTA), 0.5% SDS, 100 g/mL denatured salmonat 37C in the prehybridization solution and 200 mg/mL
sperm DNA] containing a 32P c-DNA probe labeled withsonicated denatured herring sperm DNA (Sigma, St.
random primed DNA labeling kit (Boehringer Mann-Louis, MO, USA). Hybridization was carried out at 37C
heim Biochemica). The c-DNA probe for factor V wasovernight with a DIG-labeled antisense probe. Sections
generously donated by Dr. William H. Kane (Duke Uni-were washed for 15 minutes in 2 SSC at room tempera-
versity Medical Center, Durham, NC, USA). Signal den-ture (RT), in 1  SSC at RT for 15 minutes, 0.5  SSC
at 37C for 15 minutes, and finally washed in 0.1  SSC sities of each factor V were corrected with 18S RNA.
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Fig. 3. Immunoblotting for factor V expression. Total cellular extract
was isolated from MCs after TNF- stimulation and immunoprecipi-
tated with antifactor V antibody. Western blots were visualized again
with anti-factor V antibody. This experiment was repeated twice and
representative data are shown.
RESULTS
Factor V antigen expression in MCs
Factor V antigen was feebly stained after a 96-hour
starvation with the antibody RAHu/FV. However, the
density of factor V protein staining was significantly in-
creased after exposure to TNF- in a time-dependent
manner (Fig. 1). As shown in Figure 2A, the percent
density of factor V staining was augmented with time in
the presence of 100 U/mL TNF- and was increased to
6.3-fold after 24 hours (P  0.01 by ANOVA). Figure
2B shows the dose-dependent increase in factor V stain-
ing after TNF- stimulation for 24 hours (P  0.01 by
ANOVA). The percent density of the staining was sig-
nificantly increased after TNF- stimulation to 3.5- and
4.5-fold at concentrations of 50 and 100 U/mL, respec-
tively. To confirm the expression of factor V protein,
MCs were analyzed by immunoblotting (Fig. 3). FactorFig. 2. Augmentation of factor V production by TNF- stimulation.
V protein was increasingly detected following TNF-(A) Time-dependent accumulation of factor V in percent density (quan-
tification of the experiment in Fig. 1). Fifteen cells in each experimental stimulation at the band of approximately 300,000 molec-
setting were analyzed from five areas after immunostaining. Significant
ular weight, which corresponded to the previously re-effects of the addition of TNF- in promoting the expression of factor
V were observed. **P  0.01. (B) Dose-dependent increases in factor ported scale [16].
V production by TNF- stimulation were indicated by percent density.
This experiment was repeated three times. Representative data are Formation of cell surface XFb by endogenous factorshown. Fifteen cells in each experimental setting were analyzed from
Va activity with exogenous factor Xafive areas after immunostaining. Significant effects of the addition of
TNF- in promoting the expression of factor V were observed. *P  Formation of XFb in time progression. Cross-linked0.05; **P  0.01.
fibrin (XFb) production on MCs was evaluated immuno-
histochemically using the anti-d-dimer antibody, DD3B6/22,
after plasmin exposure. XFb formation was augmented
on the MCs’ surface after the addition of coagulation
Statistics factors of Xa, prothrombin, XIII, and fibrinogen (Fig.
4). As shown in Figure 5, the percent density of FXbStatistical evaluation was performed using a one-way
staining was augmented by progress of time and wasanalysis of variance (ANOVA) or the Student t test, as
increased to 26.3-fold after 120 minutes (P  0.0001 byappropriate. The values are reported as mean  SD,
and statistical significance was set at P  0.05. ANOVA).
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Fig. 4. Cross-linked fibrin (XFb) production
on MCs after incubation with coagulation fac-
tors. XFb was produced on TNF-–stimulated
MCs after 0 (A, control), 15 (B), 60 (C), and
120 minutes of (D) incubation with factor Xa,
prothrombin, factor XIII, and fibrinogen. XFb
staining was increasingly observed in a time-
dependent manner. This experiment was re-
peated twice and representative data are shown
(final magnification, 190).
hybridization showed the presence of factor V transcripts
in MCs. Factor V mRNA was expressed in MCs three
hours after incubation with 100 U/mL of TNF- (Fig. 8).
Northern blot analysis. To characterize the ability of
the cytokine TNF- to regulate the factor V gene expres-
sion in MCs more completely, Northern blot analyses of
total RNA from cultured MCs were performed. Densito-
metric analysis of autoradiographs from Northern blots
of factor V transcripts corrected with 18S RNA demon-
strated time-dependent increases in expression after
TNF- exposure as 7.9- and 14.8-fold the control value
after three and six hours, respectively (Fig. 9).
Fig. 5. Percent density of XFb on MCs (quantification of the experi- DISCUSSION
ment in Fig. 3). Fifteen cells in each experimental setting were analyzed
from five areas after immunostaining. A significant increase of XFb After starting the coagulation process, factor V is
formation was observed by ANOVA (P  0.0001). transformed into factor Va through targeted proteolytic
cleavage and plays a principle role in the coagulation
cascade. As a membrane-bound cofactor to factor Xa,
Blocking test using anti-factor V antibody factor Va forms a Xa/Va complex, which converts pro-
thrombin to thrombin. After thrombin transforms fi-The addition of neutralizing antibody RAHu/FV
brinogen to fibrin [17], stabilized fibrin is produced bycaused a significant inhibition of XFb production on MC
cross-linking of fibrin monomer in the presense of factorsurfaces in a dose-dependent manner (Fig. 6). As shown
XIIIa. Factor V production has been reported in plateletsin Figure 7, the percent density of XFb staining was
[18, 19], endothelial cells [20], monocytes [21], and hepa-decreased to 42.4 and 5.8% of the control in the presence
tocytes [22]. Factor V circulates in the blood as an inac-of 25 and 50 g/mL of RAHu/FV, respectively (P  0.01
tive cofactor or is bound on cell surfaces with low intrin-by ANOVA).
sic activity and is converted to its active form Va by
Detection of factor V mRNA in MCs thrombin or Xa [23].
Intraglomerular coagulation is thought to be involvedIn situ hybridization. In an experiment examining fac-
tor V gene expression after TNF- stimulation, in situ in the development of glomerular injury [24, 25]. We
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Fig. 6. Inhibitory effect of anti-factor V anti-
body on XFb production. XFb staining density
was dose-dependently suppressed by the addi-
tion of anti-factor V antibody. This experi-
ment was repeated twice and representative
data are shown: control (A), 25 (B), and 50
mg/mL of IgG (C; final magnification, 210).
Fig. 8. In situ hybridization of factor V mRNA
expression in MCs. Light micrographs of fast
red dye show in situ hybridization using DIG-
labeled oligonucleotidedes probes with hema-
toxylin counter staining. Factor V transcripts
hybridized with the anti-sense probe were
present in MCs (A), while the transcripts were
abolished by 50-fold cold excess of unlabeled
probes (B; final magnification, 280).
and other authors have observed various coagulation ceeds on the surface of cultured MCs via expression of
factor V after the stimulation of inflammatory cytokinefactors in glomeruli of renal biopsy specimens [8, 26–29].
Glomerular expression of tissue factor is known to be TNF-.
In the present study, factor V is expressed by culturedup-regulated in human crescentic glomerulonephritis [30].
In the recent study by Cunningham et al, tissue factor human MCs, which were increased after stimulation with
TNF-, is active on the MCs’ surface after activatingpathway inhibitor is shown to be dysregulated in the
early stages of human crescentic glomerulonephritis when treatment with factor Xa and capable of producing XFb
deposition on its cell surface. This XFb formation viathere is significant fibrin deposition [31]. Previously, we
observed increasing immunoreactivity after plasmin ex- factor V expression was confirmed further by the blocking
test using factor V-neutralizing antibody. By in situ hy-posure using the monoclonal antibody DD3B6/22, in
renal biopsy specimens both from IgA nephropathy and bridization and Northern blotting, factor V mRNA ex-
pression was present after TNF- stimulation. AnotherHenoch-Scho¨nlein purpura nephritis, which showed the
existence of intact XFb in glomeruli [1]. Our more recent proinflammatory cytokine, interleukin-6 (IL-6), tested
the stimulus effect of factor V production. After IL-6clinicopathological study found a close relationship be-
tween factor V expression and MC proliferation in IgA (0.5 ng/mL) stimulation for 24 hours, factor V protein
expression also increased (data not shown). Therefore,nephropathy [6]. That report used human renal biopsy
specimens from nearly normal or diseased tissue to show it is obvious that factor V is produced in cultured MCs.
The dose of recombinant TNF- (100 U/mL) corre-that in the physiological state, factor V expression is weak
or absent in glomeruli and is up-regulated in the active sponds to 1.7 ng/mL. It was reported that patients with
IgA nephropathy had an increased plasma level of TNF-type of IgA nephropathy. Therefore, our current study
further examined whether this coagulation process pro- (18.1 pg/mL) compared with that in controls (12.3 pg/mL)
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Fig. 9. Effects of the addition of recombinant TNF- on the expression
of factor V mRNA. Signal density of factor V mRNA was corrected with
18S of total RNA. Factor V transcripts increased in a time-dependent
manner up to six hours after TNF- stimulation. This experiment was
Fig. 7. Percent density of XFb in inhibition by anti-factor V antibody repeated three times and representative data are shown.
(quantification of the experiment in Fig. 4). Fifteen cells in each experi-
mental setting were analyzed from five areas after immunostaining.
Significant effects of the addition of anti-factor V antibody in inhibiting
the production of XFb on MCs were observed. **P 0.01 by ANOVA.
formed MCs presented factor V expression by the simul-
taneous in situ detection of factor V mRNA and antigen
staining of -smooth muscle actin in the active type of IgA
nephropathy [6]. From preliminary findings, mesangial[32]. The in vitro dose was nearly 100-fold greater than
the in vivo plasma level in glomerulonephritis. However, factor V expression and fibrin-related antigen deposition
were markedly high in antithymocyte serum-injectedYoshioka et al reported increased TNF- expression in
the glomeruli in patients with IgA nephropathy, using rats, and this fibrin deposition decreased by the simulta-
neous anti-factor V antibody injection (abstract; Ono etin situ hybridization [33]. Therefore, the local concentra-
tion of TNF- in the mesangial areas could reach the in al, J Am Soc Nephrol 11:497A, 2000). Our present study
observed potent endogenous factor Va activity on cul-vitro level in the present study.
Mesangial cells are known to express other coagula- tured MC surfaces, not only at the protein level but
also with mRNA expression. Therefore, the activator oftion and fibrinolysis factors. Tissue factor is expressed in
MCs by TNF- stimulation [4] and is the principle initiator prothrombin in our study consists of endogenous factor
V in MCs. To our knowledge, this is the first evidenceof the extrinsic coagulation pathway. Other authors re-
ported that cultured MCs induce antifibrinolytic activity that MCs, which are adjacent to fenestrated endothelium
in vivo and are supplied with various coagulation factorsthrough the expression of plasminogen activator inhibi-
tor-1 (PAI-1) [34], and that extracellular matrix degrada- from blood circulation through fenestration of glomeru-
lar capillary endothelium [39], can activate prothrombintion by cultured human MCs was mediated by plasmin/
matrix metalloproteinase-2 cascade and ameliorated by through endogenous factor V production together with
exogenous factor Xa.the depletion of PAI-1 [35]. On the other hand, thrombo-
modulin also is known to be produced in MCs and acts Several authors have reported the significance of the
extrinsic tissue factor pathway in glomerulonephritis [30,beneficially by preventing local fibrin formation [36].
The role of factor V in MCs can be compared to that 31, 40]. The majority of patients described in these re-
ports demonstrated acute crescentic glomerulonephritis,of tissue factor, which also acts at their membrane surface.
The site of factor V is active in the final stage of pro- including anti-neutrophil cytoplasmic antibody-related
glomerulonephritis. However, our previous in vivo studythrombin activation, in contrast to tissue factor, which
initiates the cascade. Even when tissue factor starts the observed that mesangial factor V expression colocalized
with fibrin deposition in the mesangium in IgA nephrop-coagulation cascade, prothrombin cannot be converted
to thrombin without prothrombinase Xa/Va or another athy [6]. Kaizuka et al reported that thrombin stimulates
synthesis of type IV collagen and tissue inhibitor of met-activating protease. In the previous study, Sekiya et al
reported that some cell lines other than MCs express an alloproteinases-1 by cultured human MCs [41]. It is tempt-
ing to speculate that in chronic mesangioproliferativeunknown activator of prothrombin on their surface [37].
Their recent study reported that prothrombin activation glomerulonephritis, endogenous factor V expression in
MCs may be predominant and plays a role in formingoccurred on fibroblasts, glial, and neuronal cells in a
manner dependent on both exogenous factor Xa and mesangial matrix expansion, in contrast to tissue factor
which is prominent in acute crescentic glomerulonephritis.factor Va [38]. Recently, we have shown that trans-
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Fig. 10. Schematic depiction of the role of
endogenous factor V on MC surfaces in the
coagulation process. (A) Factor V expression
is weak in quiescent MCs. (B) After inflam-
matory stimulation of TNF-, endogenous
factor V is expressed in MCs. (C) Other coagu-
lation factors: prothrombin, fibrinogen, factor
Xa, and XIII, are supplied through the fenes-
tration of endothelial cells. Factor V converts
into its active form, Va by Xa, forming pro-
thrombinase, Xa/Va, and prothrombin activa-
tion proceeds on MCs surface. Thrombin con-
verts fibrinogen to fibrin monomer and XIII
to XIIIa, respectively. The fibrin monomer
homopolymerizes to form long strands, and
cross-linked fibrin is covalently produced on
MCs by the action of factor XIIIa.
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